Name | KO947 |
---|---|
Synonyms | KO-947 |
Description | KO-947 is a potent and selective inhibitor of ERK1/2 kinases with potential clinical utility in MAPK pathway dysregulated tumors. |
---|---|
Related Catalog | |
Target |
ERK1 ERK2 |
In Vitro | KO-947 is a 10 nM inhibitor of ERK with at least 50-fold selectivity against a panel of 450 kinases. KO-947 blocks ERK signaling and proliferation of tumor cells exhibiting dysregulation of MAPK pathway signaling, including mutations in BRAF, NRAS or KRAS, at low nanomolar concentrations[1]. |
In Vivo | In cell-line derived xenograft studies, KO-947 profoundly suppresses ERK signaling for up to five days after a single dose and induces regressions in RAS- and RAF-mutant melanoma, NSCLC and pancreatic cancer models on administration schedules ranging from daily to weekly. Intermittent dosing enables comparable antitumor activity at reduced dose-intensity[1]. |
References |
Molecular Formula | C21H17N5O |
---|---|
Molecular Weight | 355.4 |
Storage condition | 2-8℃ |